Healthcare provider profile · identity verified

Peter Montgomery, MD

Allopathic & Osteopathic Physicians|Family Medicine · WENTZVILLE, MO · NPI 1558356469

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Peter Montgomery, MD received $183.43 in general payments during 2025 across 2 reported records.

Lilly USA, LLC accounted for 60.7% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trulicity by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Ozempic by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$183.43

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Lilly USA, LLC	Unresolved — no canonical attribution shown	$111.28	60.7%	1	2025
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$72.15	39.3%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$183.43	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Wegovy Normalized: wegovy	Drug	Novo Nordisk Inc	$72.15	1	2025
Source payment records 2025-02-20 · Novo Nordisk Inc · $72.15 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	40	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	124	26
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	73	16
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	151	30

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	885	251
Losartan Potassium	Losartan Potassium	558	157
Lisinopril	Lisinopril	523	139
Pantoprazole Sodium	Pantoprazole Sodium	503	155
Amlodipine Besylate	Amlodipine Besylate	482	136
Quetiapine Fumarate	Quetiapine Fumarate	440	110
Levothyroxine Sodium	Levothyroxine Sodium	434	120
Omeprazole	Omeprazole	398	106
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	370	64
Albuterol Sulfate Hfa	Albuterol Sulfate	339	76
Metformin Hcl Er	Metformin Hcl	321	93
Gabapentin	Gabapentin	312	76
Alprazolam	Alprazolam	308	69
Metoprolol Succinate	Metoprolol Succinate	306	87
Tamsulosin Hcl	Tamsulosin Hcl	280	83
Tramadol Hcl	Tramadol Hcl	267	65
Prednisone	Prednisone	261	174
Glimepiride	Glimepiride	253	62
Rosuvastatin Calcium	Rosuvastatin Calcium	253	86
Furosemide	Furosemide	226	69
Metoprolol Tartrate	Metoprolol Tartrate	214	58
Famotidine	Famotidine	207	51
Clopidogrel	Clopidogrel Bisulfate	203	54
Potassium Chloride	Potassium Chloride	188	57
Meloxicam	Meloxicam	185	58
Metformin Hcl	Metformin Hcl	183	50
Escitalopram Oxalate	Escitalopram Oxalate	172	47
Hydrochlorothiazide	Hydrochlorothiazide	172	52
Fluticasone Propionate	Fluticasone Propionate	170	56
Pravastatin Sodium	Pravastatin Sodium	170	48
Simvastatin	Simvastatin	165	43
Carvedilol	Carvedilol	160	47
Tizanidine Hcl	Tizanidine Hcl	156	40
Eliquis	Apixaban	154	42
Ozempic	Semaglutide	151	30
Finasteride	Finasteride	148	45
Duloxetine Hcl	Duloxetine Hcl	144	31
Sertraline Hcl	Sertraline Hcl	134	42
Mounjaro	Tirzepatide	124	26
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	120	29
Pioglitazone Hcl	Pioglitazone Hcl	120	38
Ondansetron Hcl	Ondansetron Hcl	118	25
Montelukast Sodium	Montelukast Sodium	113	27
Diclofenac Sodium	Diclofenac Sodium	108	36
Allopurinol	Allopurinol	106	33
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	102	36
Isosorbide Mononitrate Er	Isosorbide Mononitrate	102	27
Arexvy	Rsvpref3 Antigen/As01e/Pf	99	99
Amoxicillin	Amoxicillin	98	83
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	98	32
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	93	27
Venlafaxine Hcl Er	Venlafaxine Hcl	92	14
Citalopram Hbr	Citalopram Hydrobromide	91	26
Fluoxetine Hcl	Fluoxetine Hcl	90	24
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	88	23
Lovastatin	Lovastatin	87	20
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	86	15
Alendronate Sodium	Alendronate Sodium	85	28
Bupropion Xl	Bupropion Hcl	85	21
Gemfibrozil	Gemfibrozil	83	22
Lorazepam	Lorazepam	83	25
Sumatriptan Succinate	Sumatriptan Succinate	82	17
Diazepam	Diazepam	75	13
Trulicity	Dulaglutide	73	16
Doxycycline Hyclate	Doxycycline Hyclate	72	56
Terazosin Hcl	Terazosin Hcl	69	17
Warfarin Sodium	Warfarin Sodium	69	19
Atenolol	Atenolol	68	16
Ciprofloxacin Hcl	Ciprofloxacin Hcl	65	54
Spironolactone	Spironolactone	65	25
Amitriptyline Hcl	Amitriptyline Hcl	62	17
Ropinirole Hcl	Ropinirole Hcl	62	16
Pregabalin	Pregabalin	58	13
Nystatin	Nystatin	57	30
Hydroxyzine Hcl	Hydroxyzine Hcl	56	12
Propranolol Hcl	Propranolol Hcl	56	14
Vitamin D2	Ergocalciferol (Vitamin D2)	55	16
Acyclovir	Acyclovir	54	21
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	54	19
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	54	13
Donepezil Hcl	Donepezil Hcl	53	13
Ezetimibe	Ezetimibe	51	14
Prazosin Hcl	Prazosin Hcl	50	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	49	11
Esomeprazole Magnesium	Esomeprazole Magnesium	49	suppressed
Memantine Hcl	Memantine Hcl	48	11
Trazodone Hcl	Trazodone Hcl	48	12
Celecoxib	Celecoxib	47	11
Oxybutynin Chloride	Oxybutynin Chloride	47	11
Sucralfate	Sucralfate	46	15
Ventolin Hfa	Albuterol Sulfate	46	14
Cilostazol	Cilostazol	44	suppressed
Clonazepam	Clonazepam	44	suppressed
Buspirone Hcl	Buspirone Hcl	42	suppressed
Estradiol	Estradiol	42	12
Hydralazine Hcl	Hydralazine Hcl	40	12
Jardiance	Empagliflozin	40	suppressed
Temazepam	Temazepam	40	suppressed
Symbicort	Budesonide/Formoterol Fumarate	39	12
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	37	suppressed
Clonidine Hcl	Clonidine Hcl	36	suppressed
Olanzapine	Olanzapine	36	suppressed
Oxycodone Hcl	Oxycodone Hcl	36	suppressed
Topiramate	Topiramate	36	suppressed
Xarelto	Rivaroxaban	35	suppressed
Breo Ellipta	Fluticasone/Vilanterol	34	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	34	suppressed
Primidone	Primidone	34	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	34	23
Synthroid	Levothyroxine Sodium	33	suppressed
Nifedipine Er	Nifedipine	32	suppressed
Azithromycin	Azithromycin	31	29
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	30	30
Glipizide	Glipizide	30	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	29	suppressed
Amiodarone Hcl	Amiodarone Hcl	28	11
Meclizine Hcl	Meclizine Hcl	28	11
Paroxetine Hcl	Paroxetine Hcl	28	suppressed
Spiriva Respimat	Tiotropium Bromide	28	suppressed
Cefdinir	Cefdinir	27	25
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	27	14
Fluconazole	Fluconazole	27	22
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	24	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	24	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	24	suppressed
Glipizide Er	Glipizide	24	suppressed
Nitroglycerin	Nitroglycerin	24	13
Spiriva Handihaler	Tiotropium Bromide	24	suppressed
Chlorthalidone	Chlorthalidone	23	suppressed
Levofloxacin	Levofloxacin	23	22
Prochlorperazine Maleate	Prochlorperazine Maleate	23	suppressed
Valacyclovir	Valacyclovir Hcl	23	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	22	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	22	suppressed
Midodrine Hcl	Midodrine Hcl	22	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	22	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	22	suppressed
Divalproex Sodium Er	Divalproex Sodium	21	suppressed
Folic Acid	Folic Acid	21	suppressed
Ibuprofen	Ibuprofen	21	suppressed
Methotrexate	Methotrexate Sodium	20	suppressed
Mirtazapine	Mirtazapine	20	suppressed
Risperidone	Risperidone	20	suppressed
Terbinafine Hcl	Terbinafine Hcl	20	suppressed
Methocarbamol	Methocarbamol	19	suppressed
Testosterone Cypionate	Testosterone Cypionate	19	suppressed
Calcitonin-Salmon	Calcitonin,salmon,synthetic	18	suppressed
Myrbetriq	Mirabegron	18	suppressed
Premarin	Estrogens, Conjugated	18	suppressed
Ramipril	Ramipril	18	suppressed
Dexamethasone	Dexamethasone	17	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	17	suppressed
Divalproex Sodium	Divalproex Sodium	17	suppressed
Dutasteride	Dutasteride	17	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Digoxin	Digoxin	16	suppressed
Doxepin Hcl	Doxepin Hcl	16	suppressed
Fenofibrate	Fenofibrate	16	suppressed
Klor-Con M20	Potassium Chloride	16	suppressed
Metronidazole	Metronidazole	16	13
Insulin Lispro Kwikpen U-100	Insulin Lispro	15	suppressed
Januvia	Sitagliptin Phosphate	15	suppressed
Lidocaine	Lidocaine	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	15	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Clobetasol Propionate	Clobetasol Propionate	14	suppressed
Diltiazem Hcl	Diltiazem Hcl	14	suppressed
Levetiracetam	Levetiracetam	14	suppressed
Procto-Med Hc	Hydrocortisone	14	suppressed
Clindamycin Hcl	Clindamycin Hcl	13	13
Entresto	Sacubitril/Valsartan	13	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Methenamine Hippurate	Methenamine Hippurate	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Ranolazine Er	Ranolazine	13	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	12	suppressed
Enulose	Lactulose	12	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	12	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	12	suppressed
Jantoven	Warfarin Sodium	12	suppressed
Letrozole	Letrozole	12	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	12	suppressed
Mupirocin	Mupirocin	12	suppressed
Potassium Citrate Er	Potassium Citrate	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	11	suppressed
Armodafinil	Armodafinil	11	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	11	suppressed
Brilinta	Ticagrelor	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed
Leflunomide	Leflunomide	11	suppressed
Loperamide	Loperamide Hcl	11	suppressed
Naltrexone Hcl	Naltrexone Hcl	11	suppressed
Pentoxifylline	Pentoxifylline	11	suppressed
Testosterone	Testosterone	11	suppressed
Tiotropium Bromide	Tiotropium Bromide	11	suppressed
Torsemide	Torsemide	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$183.43 · 2 records	Lilly USA, LLC	Wegovy	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error